These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35730571)

  • 1. Time of Day of BNT162b2 COVID-19 Immunization Affects Total SARS-CoV-2 Antibody Levels but Not Neutralizing Activity.
    Filippatos F; Tatsi EB; Efthymiou V; Syriopoulou V; Michos A
    J Biol Rhythms; 2022 Oct; 37(5):562-566. PubMed ID: 35730571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1
    Michos A; Tatsi EB; Filippatos F; Dellis C; Koukou D; Efthymiou V; Kastrinelli E; Mantzou A; Syriopoulou V
    Vaccine; 2021 Sep; 39(40):5963-5967. PubMed ID: 34400017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up.
    Matusali G; Sberna G; Meschi S; Gramigna G; Colavita F; Lapa D; Francalancia M; Bettini A; Capobianchi MR; Puro V; Castilletti C; Vaia F; Bordi L
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity.
    Kawasuji H; Morinaga Y; Tani H; Saga Y; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
    Microbiol Spectr; 2021 Dec; 9(3):e0056121. PubMed ID: 34851162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
    Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
    PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
    Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
    Front Immunol; 2021; 12():728021. PubMed ID: 34646267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
    Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
    Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
    Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
    Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults.
    Erice A; Varillas-Delgado D; Caballero C
    Clin Microbiol Infect; 2022 Jan; 28(1):139.e1-139.e4. PubMed ID: 34508885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
    Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
    Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity.
    Bae S; Ko JH; Choi JY; Park WJ; Lim SY; Ahn JY; Song KH; Lee KH; Song YG; Chan Kim Y; Park YS; Choi WS; Jeong HW; Kim SW; Kwon KT; Kang ES; Kim AR; Jang S; Kim B; Kim SS; Jang HC; Choi JY; Kim SH; Peck KR
    Clin Microbiol Infect; 2022 Oct; 28(10):1390.e1-1390.e7. PubMed ID: 35598855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
    Muik A; Lui BG; Wallisch AK; Bacher M; Mühl J; Reinholz J; Ozhelvaci O; Beckmann N; Güimil Garcia RC; Poran A; Shpyro S; Finlayson A; Cai H; Yang Q; Swanson KA; Türeci Ö; Şahin U
    Science; 2022 Feb; 375(6581):678-680. PubMed ID: 35040667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.
    Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Saxton M; Piantadosi A; Waggoner JJ; Douek DC; Rouphael N; Wrammert J; Suthar MS
    Cell Rep Med; 2022 Feb; 3(2):100529. PubMed ID: 35233550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.